Title:
BRAIN-MIGRATING TUMOR THERAPEUTIC AGENT CONTAINING FUSED PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT
Document Type and Number:
WIPO Patent Application WO/2022/107864
Kind Code:
A1
Abstract:
The present invention addresses the problem of providing a brain-migrating antitumor agent that exhibits excellent brain migration properties and RET inhibitory activity. The present invention provides a brain-migrating antitumor agent that contains a compound represented by general formula (I) (wherein R1, R2 and R3 are as described in the specification) or a salt thereof as an active ingredient.
More Like This:
| JP2004277337 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE |
| JP2022520997 | How to use imipridon |
| WO/2010/116176 | PYRAZOLO [4, 5-E] PYRIMIDINE DERIVATIVE AND ITS USE TO TREAT DIABETES AND OBESITY |
Inventors:
MIYAZAKI ISAO (JP)
IGUCHI SATORU (JP)
WAKAYAMA KENTARO (JP)
IGUCHI SATORU (JP)
WAKAYAMA KENTARO (JP)
Application Number:
PCT/JP2021/042502
Publication Date:
May 27, 2022
Filing Date:
November 18, 2021
Export Citation:
Assignee:
TAIHO PHARMACEUTICAL CO LTD (JP)
International Classes:
A61K31/519; A61K31/5377; A61K31/541; A61P25/00; A61P35/00; A61P35/04; C07D487/04
Domestic Patent References:
| WO2017146116A1 | 2017-08-31 | |||
| WO2020145374A1 | 2020-07-16 | |||
| WO2017146116A1 | 2017-08-31 |
Foreign References:
| JP2019182865A | 2019-10-24 | |||
| JP2019182806A | 2019-10-24 | |||
| JP2020193073A | 2020-12-03 |
Other References:
QINGBEI ZENG, JMED CHEM. 22, vol. 58, no. 20, 2015, pages 8200 - 15
LAKSHMINAYAK, CURR ONCOL REP, vol. 14, no. 1, 2012, pages 48 - 54
BRUNILDE GRIL, EUR J CANCER, vol. 46, no. 7, 2010, pages 1204 - 10
TAOFEEKK. OWONIKOKO, NAT REVCLIN ONCOL, vol. 11, no. 4, 2014, pages 203 - 22
CHIEN-HUNG GOW, CLIN CANCER RES. 1, vol. 14, no. 1, 2008, pages 162 - 8
WILLIAM M. PARDRIDGE, J NEUROCHEM, vol. 70, no. 5, 1998, pages 1781 - 92
TED W. JOHNSON, J MED CHEM. 12, vol. 57, no. 11, 2014, pages 4720 - 44
LOISM.MULLIGAN, NATUREREV, vol. 14, no. 3, 2014, pages 173 - 186
CARLOS F. IBANEZ, COLD SPRING HARB PERSPECT BIO, vol. 5, no. 2, 2013, pages 1 - 10
TAKASHI KOHNO, NATURE MED, vol. 18, no. 3, 2012, pages 375 - 377
MASSIMO SANTORO, EUR J ENDOCRINOL, vol. 155, 2006, pages 645 - 653
MARJAN ZARIF YEGANEH, ASIAN PAC J CANCER PREV, vol. 16, no. 6, 2015, pages 2107 - 2117
ALBANA GATTELLI, EMBO MOL MED, vol. 5, 2013, pages 1335 - 1350
YOSHINORI ITO, SURGERY, vol. 138, 2005, pages 788 - 794
DAWNM. DAWSON, J NATL CANCER INST, vol. 90, 1998, pages 519 - 523
WEIJING CAI, CANCER, vol. 119, 2013, pages 1486 - 1494
ROSSELLA ELISEI, JCLIN ENDOCRINOL METAB, vol. 93, no. 3, 2008, pages 682 - 687
Q ZENG, J. INT. MED. RES, vol. 36, 2008, pages 656 - 664
FRANCESCA CARLOMAGNO, CANCER RES, vol. 62, no. 4, 2002, pages 1077 - 1082
LOUISE TATTON, JBIOLCHEM, vol. 278, no. 7, 2003, pages 4847 - 4853
MARKUS WARMUTH, BLOOD, vol. 101, no. 2, 2003, pages 664 - 672
CAROLYN LOWE, PROC NATL ACAD SCI USA, vol. 90, no. 10, 1993, pages 4485 - 9
THIERRYMOLINA, NATURE, vol. 357, no. 6374, 1992, pages 161 - 4
"Molecular Design", vol. 7, 1990, HIROKAWA SHOTEN CO, article "Iyakuhin no Kaihatsu [Development of Pharmaceuticals", pages: 163 - 198
VARADHARAJ AN, S ET AL., J PHARM SCI, vol. 104, 2015, pages 1197 - 1206
LAKSHMINAYAK, CURR ONCOL REP, vol. 14, no. 1, 2012, pages 48 - 54
BRUNILDE GRIL, EUR J CANCER, vol. 46, no. 7, 2010, pages 1204 - 10
TAOFEEKK. OWONIKOKO, NAT REVCLIN ONCOL, vol. 11, no. 4, 2014, pages 203 - 22
CHIEN-HUNG GOW, CLIN CANCER RES. 1, vol. 14, no. 1, 2008, pages 162 - 8
WILLIAM M. PARDRIDGE, J NEUROCHEM, vol. 70, no. 5, 1998, pages 1781 - 92
TED W. JOHNSON, J MED CHEM. 12, vol. 57, no. 11, 2014, pages 4720 - 44
LOISM.MULLIGAN, NATUREREV, vol. 14, no. 3, 2014, pages 173 - 186
CARLOS F. IBANEZ, COLD SPRING HARB PERSPECT BIO, vol. 5, no. 2, 2013, pages 1 - 10
TAKASHI KOHNO, NATURE MED, vol. 18, no. 3, 2012, pages 375 - 377
MASSIMO SANTORO, EUR J ENDOCRINOL, vol. 155, 2006, pages 645 - 653
MARJAN ZARIF YEGANEH, ASIAN PAC J CANCER PREV, vol. 16, no. 6, 2015, pages 2107 - 2117
ALBANA GATTELLI, EMBO MOL MED, vol. 5, 2013, pages 1335 - 1350
YOSHINORI ITO, SURGERY, vol. 138, 2005, pages 788 - 794
DAWNM. DAWSON, J NATL CANCER INST, vol. 90, 1998, pages 519 - 523
WEIJING CAI, CANCER, vol. 119, 2013, pages 1486 - 1494
ROSSELLA ELISEI, JCLIN ENDOCRINOL METAB, vol. 93, no. 3, 2008, pages 682 - 687
Q ZENG, J. INT. MED. RES, vol. 36, 2008, pages 656 - 664
FRANCESCA CARLOMAGNO, CANCER RES, vol. 62, no. 4, 2002, pages 1077 - 1082
LOUISE TATTON, JBIOLCHEM, vol. 278, no. 7, 2003, pages 4847 - 4853
MARKUS WARMUTH, BLOOD, vol. 101, no. 2, 2003, pages 664 - 672
CAROLYN LOWE, PROC NATL ACAD SCI USA, vol. 90, no. 10, 1993, pages 4485 - 9
THIERRYMOLINA, NATURE, vol. 357, no. 6374, 1992, pages 161 - 4
"Molecular Design", vol. 7, 1990, HIROKAWA SHOTEN CO, article "Iyakuhin no Kaihatsu [Development of Pharmaceuticals", pages: 163 - 198
VARADHARAJ AN, S ET AL., J PHARM SCI, vol. 104, 2015, pages 1197 - 1206
Attorney, Agent or Firm:
SAEGUSA & PARTNERS (JP)
Download PDF: